Conference call

Star Equity Holdings, Inc. Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Friday, March 22, 2024
Conference call, Conference, Construction, Exhibit, Webcast, Star, Sale, Acquisition, Security (finance), Loss, Event, Depreciation, Investment, Reinsurance

OLD GREENWICH, Conn., March 22, 2024 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company, reported today its financial results for the fourth quarter (Q4) and fiscal year (FY) ended December 31, 2023. All 2023 and 2022 amounts in this release are unaudited.

Key Points: 
  • FY 2023 Construction gross profit decreased 4.0% from the prior year period also due to lower revenue.
  • However, we have significantly increased prices to offset higher input costs and have seen an improvement in our gross margin percentage in 2023.
  • Q4 2023 sales, general and administrative (SG&A) expenses decreased $1.0 million versus Q4 2022.
  • SG&A expenses as a percentage of revenue decreased in Q4 2023 to 22.8% versus 23.9% in Q4 2022.

SEALSQ Corp Announces 2023 Fiscal Year Results

Retrieved on: 
Thursday, March 21, 2024
Well, Consumer, Medical device, EV, Annual report, Conference, Smart, Growth, SCS, Internet of things, Form, Machine, Electric vehicle, Kyōto Station, Research, Container, Bank statement, Industrial, Conference call, Investment, Semiconductor, Smart meter, Ecosystem, Post-quantum cryptography, Chips Act, PKI, Engineering, FPGA

SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a leader in the development and sales of semiconductors, PKI, and post-quantum technology hardware and software products, today announced its full year results for the period ending December 31, 2023 (FY 2023).

Key Points: 
  • SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a leader in the development and sales of semiconductors, PKI, and post-quantum technology hardware and software products, today announced its full year results for the period ending December 31, 2023 (FY 2023).
  • Gross profit of $14.0 million in FY 2023, $4.2 million higher than the gross profit of $9.8 million in FY 2022.
  • Carlos Moreira, CEO of SEALSQ noted, “Our fiscal 2023 results demonstrated the strength of our business today and present a solid foundation for future growth.
  • SEALSQ filed its annual report on Form 20-F (the "Form 20-F") for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission on March 21, 2024.

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, American Heart Association, Administration, Conference call, Conference, Target, Obesity, Prevalence, CKD, Part, Patient, SGLT2, G&A, Pivotal, Insurance, Investment, Research and development, AHA, Therapy, EGFR, Senior management, Safety, Chronic kidney disease, Hypertension, Leptin, BMI, Aldosterone, Pharmaceutical industry

RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2023, and provided a corporate update.

Key Points: 
  • R&D expenses for the quarter ended December 31, 2023 were $23.7 million, compared to $7.8 million for the quarter ended December 31, 2022.
  • G&A expenses were $4.0 million for the quarter ended December 31, 2023, compared to $2.2 million for the quarter ended December 31, 2022.
  • Total other income, net was $3.3 million for the quarter ended December 31, 2023, compared to $0.9 million for the quarter ended December 31, 2022.
  • Net loss was $24.4 million for the quarter ended December 31, 2023, compared to $9.1 million for the quarter ended December 31, 2022.

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Security (finance), WHIM, WHIM syndrome, Conference call, Conference, RPD, New Drug Application, Ageing, Orphan, Wart, NDA, Priority review, Research and development, Immune system, File, ID, FDA, X4, PDUFA, Pharmaceutical industry

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted key 2023 events and expected upcoming milestones.

Key Points: 
  • “Following an incredibly productive 2023, we are expecting a transformative year in 2024,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .
  • Following the completion of the call, a webcast replay of the conference call will be available on the company website.

FANHUA Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Open Platform, MDRT, Conference call, Conference, Growth, H.10, RMB, Intelligence, Education, Specialization, Digitalization, FYP, Travel, City, Policy, ADS, Insurance, Translation, Open platform, Investment, Depreciation, Share repurchase, Total, GWP, Video game

Operating margin was 2.7% for the fourth quarter of 2023, compared to 11.1% for the corresponding period in 2022.

Key Points: 
  • Operating margin was 2.7% for the fourth quarter of 2023, compared to 11.1% for the corresponding period in 2022.
  • Net margin was -4.5% for the fourth quarter of 2023, as compared to 9.2% for the corresponding period in 2022.
  • Adjusted EBITDA margin3 was 6.7% for the fourth quarter of 2023, as compared to 10.0% for the corresponding period in 2022.
  • The Company will host a conference call to discuss its fourth quarter and fiscal year 2023 financial results as per the following details.

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Retrieved on: 
Wednesday, March 20, 2024
Research, Teriparatide, Conference call, Conference, Obesity, Serum, SAN, Weight loss, Female, Adalimumab, Volunteering, Human, Society, Osteoporosis, Workforce, Expansion, Growth, GIP, Business operations, GLP, Animal, HC, Pharmaceutical industry

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • ET / 1:30 p.m. PT -
    SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
  • In February 2024, Rani announced RT-111 achieved high bioavailability and was well-tolerated, with no serious adverse events in humans, in a Phase 1 study.
  • In December 2023, Rani announced preclinical data demonstrating the transenteric delivery of an incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study.
  • In October 2023, Rani announced preclinical data from a 60-day, repeat oral-administration GLP safety study of the RaniPill capsule in healthy animals.

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Retrieved on: 
Wednesday, March 20, 2024
Conference, Conference call, Cancer

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024.

Key Points: 
  • FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024.
  • Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time.
  • Details for the call are as follows:
    Conference call & Webcast Details:

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Host Hotels & Resorts Announces First Quarter 2024 Earnings Call to be Held on May 2, 2024

Retrieved on: 
Friday, March 15, 2024
Host Hotels & Resorts, Trust, Conference call, Conference, HST

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report first quarter 2024 financial results on Wednesday, May 1, 2024, after the market close.

Key Points: 
  • BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report first quarter 2024 financial results on Wednesday, May 1, 2024, after the market close.
  • The Company will hold a conference call to discuss its first quarter 2024 results and business outlook on Thursday, May 2, 2024, at 11:00 a.m.
  • ET.
  • Conference call access information is as follows:

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Mother, Research, Breast milk, Conference call, Development, Bill, Webcast, COVID-19, SAN, VOC, GI, Messenger, XBB, NHP, SARS-CoV-2, Insurance, Investment, Clinical trial, Antibody, Safety, Vaxart, Nextgen, Vaccine, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
  • Financial Results for the Full Year Ended December 31, 2023
    Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
  • Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2023 today, beginning at 4:30 p.m.